A phase I study of ZD0473 and docetaxel given once every three weeks in patients with advanced refractory cancer. A National Cancer Institute of Canada-Clinical Trials Group Study (NCIC CTG-IND 131)

作者： K.A. Gelmon , D. Stewart , D. Ayers , D. Fry , L. Douglas